Lam Research Corporation is a semiconductor equipment & materials business based in the US. Lam Research shares (LRCX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Lam Research employs 11,700 staff and has a trailing 12-month revenue of around $11.1 billion.
|Latest market close||$N/A|
|52-week range||$178.4354 - $585.42|
|50-day moving average||$506.3244|
|200-day moving average||$399.351|
|Wall St. target price||$492.17|
|Dividend yield||$5.2 (0.92%)|
|Earnings per share (TTM)||$17.599|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Lam Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lam Research's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lam Research's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Lam Research shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Lam Research's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7109. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lam Research's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Lam Research's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.4 billion.
The EBITDA is a measure of a Lam Research's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11.1 billion|
|Operating margin TTM||28.02%|
|Gross profit TTM||$4.6 billion|
|Return on assets TTM||14.13%|
|Return on equity TTM||50.4%|
|Market capitalisation||$81.2 billion|
TTM: trailing 12 months
There are currently 2.7 million Lam Research shares held short by investors – that's known as Lam Research's "short interest". This figure is 18.8% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Lam Research shares can be evaluated.
Lam Research's "short interest ratio" (SIR) is the quantity of Lam Research shares currently shorted divided by the average quantity of Lam Research shares traded daily (recently around 1.4 million). Lam Research's SIR currently stands at 1.99. In other words for every 100,000 Lam Research shares traded daily on the market, roughly 1990 shares are currently held short.
However Lam Research's short interest can also be evaluated against the total number of Lam Research shares, or, against the total number of tradable Lam Research shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lam Research's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lam Research shares in existence, roughly 20 shares are currently held short) or 0.0189% of the tradable shares (for every 100,000 tradable Lam Research shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lam Research.
Find out more about how you can short Lam Research stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Lam Research.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 14.47
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Lam Research's overall score of 14.47 (as at 01/01/2019) is excellent – landing it in it in the 12nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Lam Research is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.19/100
Lam Research's environmental score of 1.19 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Lam Research is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 4.84/100
Lam Research's social score of 4.84 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Lam Research is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.44/100
Lam Research's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Lam Research is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||14.47|
|Total ESG percentile||11.54|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
Dividend payout ratio: 26.57% of net profits
Recently Lam Research has paid out, on average, around 26.57% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.92% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Lam Research shareholders could enjoy a 0.92% return on their shares, in the form of dividend payments. In Lam Research's case, that would currently equate to about $5.2 per share.
While Lam Research's payout ratio might seem fairly standard, it's worth remembering that Lam Research may be investing much of the rest of its net profits in future growth.
Lam Research's most recent dividend payout was on 6 January 2021. The latest dividend was paid out to all shareholders who bought their shares by 8 December 2020 (the "ex-dividend date").
Lam Research's shares were split on a 3:1 basis on 17 March 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lam Research shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lam Research shares which in turn could have impacted Lam Research's share price.
Over the last 12 months, Lam Research's shares have ranged in value from as little as $178.4354 up to $585.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lam Research's is 1.3414. This would suggest that Lam Research's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits worldwide. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products. It also provides SPEED gapfill high-density plasma chemical vapor deposition (HDP-CVD) products; and Striker single-wafer atomic layer deposition (ALD) products that provide multiple dielectric film solutions. In addition, the company offers Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. Further, it provides Coronus bevel clean products to enhance die yield; Da Vinci, DV-Prime, EOS, and SP to address a range of wafer cleaning applications; and Metryx mass metrology systems for high precision in-line mass measurement in semiconductor wafer manufacturing. Lam Research Corporation was founded in 1980 and is headquartered in Fremont, California.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.